Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.34 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29056083 | 0.84 | ESR1 (0.36) | ESR1ESR2PBRM1SRD5A1MLNR | |
| SCHEMBL27849144 | 0.81 | ESR1 (0.56) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL10510209 | 0.81 | CYP4F2 (0.36) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL6846721 | 0.81 | HTR1A (0.51) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL1734551 | 0.81 | HTR1A (0.51) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL12435372 | 0.81 | HTR1A (0.51) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL1734549 | 0.81 | HTR1A (0.51) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL22613778 | 0.81 | ESR1 (0.39) | ESR1ESR2SRD5A1MLNRADRB2 | |
| SCHEMBL10510220 | 0.78 | DRD2 (0.37) | ESR1ESR2MLNRADRB2ADRB1 | |
| SCHEMBL10506849 | 0.77 | DRD2 (0.43) | SRD5A1DRD2DRD3HRH3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111201021-B | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118496221-A | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3691639-B1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MERCK SHARP & DOHME LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200297702-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3691639-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111201021-A | Chroman monocyclic β -lactams for use in the treatment of bacterial infections | 默沙东公司 | 2020-05-26 | — | — | CN | disclosed |
| WO-2019070492-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-5703115-A | VASOCONSTRICTORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5688952-A | VASOCONSTRICTOR INTERMEDIATES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-11-18 | — | — | US | disclosed |
| US-5624952-A | VASOCONSTRICTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-04-29 | — | — | US | disclosed |
| US-5607949-A | VASOCONTRICTORS, TREATING MIGRAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-04 | — | — | US | disclosed |
| US-5541180-A | HEADACHE THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-30 | — | — | US | disclosed |
| EP-0639192-B1 | (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS | JANSSEN PHARMACEUTICA NV (BE) | 1996-05-15 | — | — | EP | disclosed |
| EP-0639192-A1 | (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS. | JANSSEN PHARMACEUTICA NV (BE) | 1995-02-22 | — | — | EP | disclosed |
| CN-1079470-A | [(benzo two alkane, cumarone or chromene) alkylamino] alkyl substituted guanidines | JANSSEN PHARMACEUTICA NV (BE) | 1993-12-15 | — | — | CN | disclosed |
| WO-1993017017-A1 | [(BENZODIOXAN, BENZOFURAN OR BENZOPYRAN)-ALKYLAMINO] ALKYL SUBSTITUTED GUANIDINES AS SELECTIVE VASCOCONSTRICTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-02 | — | — | WO | disclosed |
| EP-0145067-B1 | DERIVATIVES OF 2,2'-IMINOBISETHANOL | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | disclosed |
| US-4654362-A | CARDIOVASCULAR DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-03-31 | — | — | US | disclosed |
| EP-0145067-A2 | Derivatives of 2,2'-iminobisethanol | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MGAM, MGAM2, CMBL | ESR1 2684/4885ESR2 3702/4885PBRM1 54/4885 |
| US-20200297702-A1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, CMBL | ESR1 2789/4885ESR2 3722/4885PBRM1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.